Details of the Drug Reposition

General Information of This Drug (ID: DMH7OIA)

Drug Name
Infliximab   DMH7OIA
Synonyms Remicade (TN)
Therapeutic Class
Immunosuppressive Agents
Drug Type
Antibody

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
7 Approved Indication(s)
Indication Name Indication ID ICD-11 Status REF
Toxic epidermal necrolysis DISIWPFR N.A. Approved [1]
Coronavirus Disease 2019 (COVID-19) DISM7GNX 1D6Y Approved [2]
Lupus nephritis DISCVGPZ 4A40.0Y Approved [3]
Crohn disease DIS2C5Q8 DD70 Approved [4]
Ulcerative colitis DIS8K27O DD71 Approved [5]
Psoriatic arthritis DISLWTG2 FA21 Approved [6]
Plaque psoriasis DISQX1LF EA90.0 Approved [7]
------------------------------------------------------------------------------------
⏷ Show the Full List of 7 Indications(s)
1 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Asthma DISW9QNS CA23 Phase 3 [7]
------------------------------------------------------------------------------------
1 Withdrawn Indication(s)
Indication Name Indication ID ICD-11 Status REF
Stevens-Johnson syndrome DISZG4YX N.A. Withdrawn [8]
------------------------------------------------------------------------------------
2 Discontinued in Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Giant cell arteritis DISSP87T 4A44.2 Discontinued in Phase 2 [9]
Rheumatoid arthritis DISTSB4J FA20 Discontinued in Phase 2 [10]
------------------------------------------------------------------------------------
1 Discontinued in Phase 1 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Ankylosing spondylitis DISRC6IR FA92.0 Discontinued in Phase 1 [11]
------------------------------------------------------------------------------------

References

1 Systemic interventions for treatment of Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), and SJS/TEN overlap syndrome. Cochrane Database Syst Rev. 2022 Mar 11;3(3):CD013130.
2 Trials of anti-tumour necrosis factor therapy for COVID-19 are urgently needed. Lancet. 2020 May 2;395(10234):1407-1409.
3 Infliximab biosimilar-induced lupus nephritis: A case report. Mod Rheumatol Case Rep. 2023 Dec 29;8(1):74-76.
4 Management of inflammatory bowel disease. Med J Aust. 2018 Sep 1;209(7):318-323.
5 Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2005 Dec 8;353(23):2462-76.
6 Efficacy and safety of biologics in psoriatic arthritis: a systematic literature review and network meta-analysis. RMD Open. 2020 Feb;6(1):e001117.
7 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5004).
8 Investigating the Impact of Methylphenidate on Neural Response in Disruptive Behavioral Disorder
9 A Trial of an Investigational Drug for the Prevention of Diarrhea Associated With Irinotecan/5FU/Leucovorin Chemotherapy in Previously Untreated Metastatic Colorectal Cancer
10 Maintenance Treatment for Ovarian Carcinoma in Remission by an Antiangiogenic Treatment Strategy
11 Phase 1 Study of CC-486 in Japanese Subjects With Hematological Neoplasms